Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are self-renewable, multipotent stem cells that regulate the phenotype and function of all immune cells that participate in anti-tumor immunity. MSCs modulate the antigen-presenting properties of dendritic cells, affect chemokine and cytokine production in macrophages and CD4+ T helper cells, alter the cytotoxicity of CD8+ T lymphocytes and natural killer cells and regulate the generation and expansion of myeloid-derived suppressor cells and T regulatory cells. As plastic cells, MSCs adopt their phenotype and function according to the cytokine profile of neighboring tumor-infiltrated immune cells. Depending on the tumor microenvironment to which they are exposed, MSCs may obtain pro- and anti-tumorigenic phenotypes and may enhance or suppress tumor growth. Due to their tumor-homing properties, MSCs and their exosomes may be used as vehicles for delivering anti-tumorigenic agents in tumor cells, attenuating their viability and invasive characteristics. Since many factors affect the phenotype and function of MSCs in the tumor microenvironment, a better understanding of signaling pathways that regulate the cross-talk between MSCs, immune cells and tumor cells will pave the way for the clinical use of MSCs in cancer immunotherapy. In this review article, we summarize current knowledge on the molecular and cellular mechanisms that are responsible for the MSC-dependent modulation of the anti-tumor immune response and we discuss different insights regarding therapeutic potential of MSCs in the therapy of malignant diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs by secretion of CXCL3, HGF, and IL-6 have a role in myeloid suppressor cell (MDSC) differentiation and in this way suppress the immune system in TME.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In innate immunity, BM-MSCs express C3aR and C5aR (Complement system receptors), as anaphylatoxin receptors, for recruitment of MSCs to the sites of damage or lesions [72, 78, 79].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, human umbilical cord-derived MSC EVs (UC-MSC EVs) contain miRNA-16-5p and miRNA-3940-5p cargos that reduce the metastatic potential of tumor cells.”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies recognized that miRNAs delivered via MSC EVs were able to inhibit the metastatic potential of tumors, as well as suppress tumor growth, angiogenesis, and invasion [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, MSCs have the potential to enhance a pro-tumor microenvironment [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Razeghian, E., Margiana, R., Chupradit, S., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Shariatzadeh, S., Tosan, F., & Jarahian, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721174 · Cited by 28
RetractedHassanzadeh, A., Altajer, A. H., Rahman, H. S., Saleh, M. M., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Zamani, M., Yaghoubi, Y., Yazdanifar, M., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686453 · Cited by 24 · cited 3×
“Despite the fact that a large number of studies demonstrated the pro-tumorigenic potential of MSCs, it has to be noted that MSCs are not constitutively immunosuppressive cells [12].”
BackgroundInfluentialRetractedMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949 · cited 2×
“Accordingly, T cells use their plasma membrane neutral amino acid transporter to import cysteine released from DCs [15].”
BackgroundHarrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Self-citationTherapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer
Weng, Z., Zhang, B., Wu, C., Yu, F., Han, B., Li, B., & Li, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01141-y · Cited by 405 · cited 3×
“Since MSCs represent an important cellular constituent of the tumor microenvironment and are able to modulate the phenotype and function of all immune cells that participate in the anti-tumor immune response [9,10], a large number of experimental studies investigated the molecular mechanisms that were responsible for…”
BackgroundDavies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2017) · Stem Cells · doi:10.1002/stem.2509 · Cited by 349 · cited 1×
“Additionally, TNF-α and IFN-γ-primed MSC2 express and secrete PDL1 and PDL2, which suppress the proliferation of TNF-α and IFN-γ-producing T cells and promote the generation and expansion of immunosuppressive Tregs [31].”
BackgroundPakravan, K., Babashah, S., Sadeghizadeh, M., Mowla, S. J., Mossahebi-Mohammadi, M., Ataei, F., Dana, N., & Javan, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0335-7 · Cited by 346
Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases
Gazdic, M., Volarevic, V., Arsenijevic, N., & Stojkovic, M. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9583-3 · Cited by 248 · cited 1×
“As plastic cells, MSCs may adopt phenotype and function under the influence of the biological factors to which they are exposed [30].”
BackgroundContribution of regulatory T cells to cancer: A review
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27553 · Cited by 195 · cited 2×
“Tregs and MDSCs express cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PDL1 and produce immunosuppressive cytokines (IL-10 and transforming growth factor beta (TGF-β)) that inhibit the proliferation, activation and effector function of CTLs and NK cells, while M2 macrophages and N2 neutrophils secrete pro-an…”
BackgroundResultMesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
Ling, W., Zhang, J., Yuan, Z., Ren, G., Zhang, L., Chen, X., Rabson, A. B., Roberts, A. I., Wang, Y., & Shi, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1656 · Cited by 194 · cited 2×
“Additionally, in the tumor microenvironment, MSC-sourced IDO prevents the trans-differentiation of Tregs in anti-tumorigenic, Th17-like cells [26].”
Background
Cited by
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Lyu, Z., Xin, M., Oyston, D. R., Xue, T., Kang, H., Wang, X., Wang, Z., & Wang, Z. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155354 · Cited by 70
The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
Zhang, X., Zhang, H., Zhang, J., Yang, M., Zhu, M., Yin, Y., Fan, X., & Yu, F. (2022) · Immunology · doi:10.1111/imm.13592 · Cited by 71
“Although mesenchymal stromal cells (MSCs) exist in various tissues, including bone marrow, fat and dental pulp, MSCs derived from different tissues have similar immunomodulatory functions and tumour homing properties to some extent [102, 103].”
BackgroundSlama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Zhong, X.-L., Huang, Y., Du, Y., He, L.-Z., Chen, Y., Cheng, Y., & Liu, H. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad172 · Cited by 44
Zhang, Y., Wang, C., & Li, J. J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00532-4 · Cited by 41
“Given that myriad factors influence the phenotype and function of MSCs within the TME [21], it holds paramount significance to further elucidate the fundamental feature of MSCs beyond the communication and coordination with tumor and immune cells in the TME.”
BackgroundKamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
“In innate immunity, BM-MSCs express C3aR and C5aR (Complement system receptors), as anaphylatoxin receptors, for recruitment of MSCs to the sites of damage or lesions [72, 78, 79].”
Harrell, C. R., Djonov, V., Volarevic, A., Arsenijević, A., & Volarević, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084378 · Cited by 30
“Moreover, pro-angiogenic factors derived from MSCs can potentially stimulate the growth of new blood vessels within the tumor microenvironment, facilitating the spread of malignant cells [27].”
BackgroundSelf-citationZhang, S., Yahaya, B. H., Pan, Y. H., Liu, Y., & Lin, J. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03551-w · Cited by 32
“Generally, the animal tumor models are established based on immunodeficient mice lacking normal immunologic function, then the MSCs-derived abundant nutritional cytokines seem to inevitably promote the growth of tumors [114, 125, 138].”
BackgroundLiu, P., An, Y., Zhu, T., Tang, S., Huang, X., Li, S., Fu, F., Ji, C., & Xuan, K. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1131218 · Cited by 26
“, 2018) while also reducing recipient CD4 and CD8 T-cell populations (Wang et al., 2018; Harrell et al., 2021).”
BackgroundDelivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma
Wang, C., Zhang, Y., Kong, W., Rong, X., Zhong, Z., Jiang, L., Chen, S., Li, C., Zhang, F., & Jiang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s471900 · Cited by 26
“158 Exosomes are extracellular vesicles (EVs) measuring 40–160 nm in diameter that carry substances from their originating cells.”
BackgroundImmunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells
Yi, Y., Fan, Z.-Q., Liu, C., Ding, Y.-T., Chen, Y., Wen, J., Jian, X.-H., & Li, Y.-F. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i3.103560 · Cited by 32
Yarahmadi, A., Dorri Giv, M., Hosseininejad, R., Rezaie, A., Mohammadi, N., Afkhami, H., & Farokhi, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472679 · Cited by 21
Calcium Phosphate Ceramics and Synergistic Bioactive Agents for Osteogenesis in Implant Dentistry
Xu, C., Sun, Y., Jansen, J. A., Li, M., Wei, L., Wu, Y., & Liu, Y. (2023) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2023.0042 · Cited by 23
“57,58 Given this, Humbert et al. hypothesized a syner-getic effect of CaP ceramics and MSCs on immunomodulation and bone formation (Fig.”
Baron, M., Drohat, P., Crawford, B., Hornicek, F. J., Best, T. M., & Kouroupis, D. (2023) · Bioengineering · doi:10.3390/bioengineering10101187 · Cited by 19
“Also, human BM-MSC EVs contain miRNA-4461 cargo that suppresses the invasive properties of tumor cells, and human AT-MSC EVs contain miRNA-15a cargo that causes the apoptosis of tumor cells [25].”
BackgroundInfluentialExosome-based advances in pancreatic cancer: The potential of mesenchymal stem cells
Rahimian, S., Mirkazemi, K., Nejad, A. K., & Doroudian, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104594 · Cited by 21
Zhang, H., Cao, X., Gui, R., Li, Y., Zhao, X., Mei, J., Zhou, B., & Wang, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113181 · Cited by 22
Mesenchymal Stem Cell–Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease
Harrell, C. R., Djonov, V., Volarevic, A., Arsenijević, A., & Volarević, V. (2025) · Journal of Ophthalmology · doi:10.1155/joph/5552374 · Cited by 19
“Although MSCs which reside in diferent organs share a large number of morphological and functional characteristics, MSCs are not homogenous cell populations [16, 17, 49].”
Self-citationMiceli, V. (2024) · World Journal of Stem Cells · doi:10.4252/wjsc.v16.i1.7 · Cited by 22
Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges
Ma, Z., Hua, J., Liu, J., Zhang, B., Wang, W., Yu, X., & Xu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043559 · Cited by 20
Taheri, M., Tehrani, H. A., Dehghani, S., Rajabzadeh, A., Alibolandi, M., Zamani, N., Arefian, E., & Ramezani, M. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.01.004 · Cited by 18
Ahn, J., Kim, B., Bello, A. B., Moon, J. J., Arai, Y., & Lee, S. (2025) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-024-00690-w · Cited by 17
A new era of gene and cell therapy for cancer: a narrative review
Wang, L., Liu, G., Zheng, L., Long, H., & Liu, Y. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-3882 · Cited by 17
Gu, C., Yang, S., Liu, X., Jin, Y., Ye, Y., & Lu, L. (2023) · Nano Research · doi:10.1007/s12274-023-5877-6 · Cited by 15
Song, P., Song, F., Shao, T., Wang, P., Li, R.-K., Chen, Z., Zhang, Z., & Xue, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1481850 · Cited by 22
“…have shown that MSCs have the ability to regulate the phagocytic capacity of neutrophils and monocytes; change the polarization of macrophages and the cytotoxicity of NK cells; and regulate the proliferation, activation, and effector functions of CD4 + and CD8 + T cells (Harrell et al., 2021).”
Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression
Rosenbaum, S. R., Fields, K. M., & Ford, H. L. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003301 · Cited by 14
“Mes-enchymal stem cells exhibit extraordinary phenotypic plasticity, and can have immune suppressive or promotional effects depending on context [133,134].”
InfluentialSun, L., Gan, J., Cai, L., Bian, F., Xu, W., & Zhao, Y. (2024) · Aggregate · doi:10.1002/agt2.537 · Cited by 10
Kucharczyk, H., Tarnowski, M., & Tkacz, M. (2025) · Molecules · doi:10.3390/molecules30244808 · Cited by 11
“MSC2s also secrete PDL1 and PDL2, inhibiting T-cell proliferation and promoting the generation of immunosuppressive Treg cells [36].”
He, Y., Li, R., She, W., Ai, Y., Li, K., Kumeria, T., Jiang, Z., Shao, Q., Zou, C., Albashari, A. A., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02218-1 · Cited by 11
“Depending on the tumor microenvironment to which they are exposed, MSCs can acquire both pro-and anti-tumor phenotypes, thereby enhancing or inhibiting tumor growth [11].”
BackgroundPignatti, E., Maccaferri, M., Pisciotta, A., Carnevale, G., & Salvarani, C. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2299729 · Cited by 11
“The aspects that require more attention concern immunogenicity of the cells [243,244], the characteristics of the culture media which must meet safety requirements [245,246], and the possible appearance of ectopic or tumor tissue [247,248].”
BackgroundAman, M., Schulte, M., Li, Y., Thomas, B., Daeschler, S. C., Mayrhofer‐Schmid, M., Kneser, U., Harhaus, L., & Böcker, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041306 · Cited by 9
“Meta-analysis of the remaining seven studies showed that treatment with MSCs increased the SFI score in rats at 2 weeks (difference in means [37], 95% confidence interval [15], fixed effect: 2.”
BackgroundResultInfluentialCancer Therapy Empowered by Extracellular Vesicle-Mediated Targeted Delivery
Chen, Y., Huang, Y., Deng, Y., Liu, X., Ye, J., Li, Q., Luo, Y., Lin, Y., Liang, R., Wei, J., et al. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00378 · Cited by 8
Lederer, C. W., Koniali, L., Buerki‐Thurnherr, T., Papasavva, P. L., Grutta, S. L., Licari, A., Štaud, F., Bonifazi, D., & Kleanthous, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040793 · Cited by 10
Zheng, J., Jiang, X., Li, Y., & Gao, J. (2023) · MedComm · doi:10.1002/mco2.313 · Cited by 8
NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand
Tang, S., Zhang, Y., Wang, P., Tang, Q., Liu, Y., Lu, F., Han, M., Zhou, M., Hu, Q. N., Feng, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112343 · Cited by 7
“…body of evidence indicating that iMSCs can mediate immunosuppression through the secretion of factors such as TGF-b , IL-10, IL-6, and PTGS2 26,41–44 and further contribute to tumor angiogenesis and growth by secreting a variety of cytokines, such as vascular endothelial growth factor (VEGF),…”
Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment
Kangari, P., Salahlou, R., & Vandghanooni, S. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.052 · Cited by 7
“54 MSCs can exhibit either pro-inflammatory or anti-inflammatory functions in an inflammatory environment.”
BackgroundPaganelli, A., Diomede, F., Marconi, G. D., Pizzicannella, J., Rajan, T. S., Trubiani, O., & Paganelli, R. (2023) · Biomedicines · doi:10.3390/biomedicines11061519 · Cited by 5
The Application of Mesenchymal Stem Cells in Future Vaccine Synthesis
Zhang, R., Duan, X., Liu, Y., Xu, J. M. S., Albashari, A. A., Ye, P., Ye, Q., & He, Y. (2023) · Vaccines · doi:10.3390/vaccines11111631 · Cited by 5
von Fournier, A., Würflein, E., Moratin, H., Stöth, M., Kasemo, T. E., Herrmann, M., Goncalves, M., Hagen, R., Hackenberg, S., Gehrke, T. E., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040231 · Cited by 5
Rühle, A., Lies, M., Strack, M., Perez, R. L., Bieber, B., Thomsen, A. R., Bronsert, P., Huber, P. E., Heß, J., Knopf, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147689 · Cited by 6
“These discrepancies in terms of the proversus anti-tumorigenic effects of MSCs may be related to differences in MSC donors and sources as well as in harvesting and culture techniques [57].”
BackgroundYe, X., Huang, W., Chen, S., Huang, F. P., & He, Y. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04901-0 · Cited by 4
Pigoń-Zając, D., Bryczek, M., Leszczuk, A., & Zając, A. (2026) · Cells · doi:10.3390/cells15110997 · Cited by 4
“Regarding MSCs, while they can promote tumor progression by suppressing anti-tumor immunity and differentiating into cancer-associated fibroblasts, a substantial body of evidence also supports their intrinsic anti-tumor effects [43,44].”
Mesenchymal stem cell-derived microRNAs: Friends or foes of tumor cells?
Harrell, C. R., Djonov, V., & Volarević, V. (2023) · PubMed · doi:10.48350/183361 · Cited by 4
Self-citationVolarević, V., Harrell, C. R., Arsenijević, A., Djonov, V., & Volarević, A. (2025) · Cells · doi:10.3390/cells14130978 · Cited by 3
“These interactions collectively result in reduced secretion of granzyme B and IFN-γ by NK cells, impairing their cytolytic function against tumor cells [23].”
InfluentialSelf-citationImplantation of human mesenchymal stromal cell pellet for therapeutic angiogenesis
Mammoto, A., Kyi, P., Scheer, M., & Mammoto, T. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.102009 · Cited by 4
Adipose MSCs response to breast cancer cell-derived factors in conditioned media and extracts
Sadeghian, F., Kazemi, F., Pirsadeghi, A., Asadi, F., Tashakori, M., & Yousefi‐Ahmadipour, A. (2024) · Cell and Tissue Banking · doi:10.1007/s10561-024-10156-x · Cited by 3
Du, Z., Sui, D., Xin, D., Tang, X., Li, M., Liu, X., Deng, Y., & Song, Y. (2024) · Journal of Liposome Research · doi:10.1080/08982104.2023.2298901 · Cited by 3
“In the TME, the inflammatory mediators TNF-a and INOS/ NOS2 are also important in antitumor immunity [45, 46].”
BackgroundDoyle, K. E., Sutter, M., Rodriguez, M., Hassan, A.-E. S., Kumar, P., & Brown, E. G. (2024) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2024.02.014 · Cited by 3
Harnessing cells to improve transport of nanomedicines
Bezze, A., Mattioda, C., Ciardelli, G., & Mattu, C. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114446 · Cited by 3
Astrocyte Autophagy in Neurodegenerative Diseases: Current Progress in Mechanisms and Therapeutics
Qian, J., Ren, S., Ren, T., Shi, R., Qiao, L., & Kang, J. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04532-6 · Cited by 3
Chen, X., Qu, Y. Q., Zhang, Y., Zhang, D. W., Yang, C., Wang, L., Zhang, H.-T., Liu, W., Law, B. Y. K., & Wong, V. K. W. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114985 · Cited by 3
Niebergall‐Roth, E., Dieter, K., Frank, M. H., & Kluth, M. A. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2419931 · Cited by 3
The role of mesenchymal stem cell-derived exosomes in tumor progression
Harrell, C. R., Djonov, V., Volarevic, A., PAVLOVIC, D., & Volarević, V. (2023) · Biocell · doi:10.32604/biocell.2023.028567 · Cited by 2
Self-citationYasumura, Y., Teshima, T., Nagashima, T., Michishita, M., Shigechika, H., Taira, Y., Suzuki, R. H., & Matsumoto, H. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2024.12.019 · Cited by 1
Papic, D., Pavlovic, D., Nićiforović, D., Jurišić, V., & Volarević, V. (2026) · Cell Transplantation · doi:10.1177/09636897251414744 · Cited by 2
“…cells also profoundly affect the phenotype and function of various immune cells-modifying antigen presentation by macrophages and dendritic cells (DCs), enhancing or suppressing the cytotoxicity of natural killer (NK) and CD8 ⁺ T cells, and altering cytokine production by CD4 ⁺ T helper cells 9 .”
Conventional and Emerging Cell Therapy Strategies
Casadei, M., Fusco, M., Cantero, M. J., Bayo, J., Malvicini, M., & Fiore, E. J. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_175 · Cited by 1
Can whole body vibration enhance chemotherapy?
Hagiu, B.-A. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111409
Kladnytska, L. V., Tomchuk, V., Velychko, V., Salata, V., & Šengaut, J. (2024) · Ukrainian journal of veterinary sciences · doi:10.31548/veterinary2.2024.102
Yıldırım, Ş., & KANDIRICI, A. (2024) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2024.4856 · Cited by 2
“31,32 However, human MSCs from the umbilical cord showed no signs of malignant transformation after up to 15 passages in vitro.”
Dias, I. E., Franchi-Mendes, T., Fernandes‐Platzgummer, A., Dias, I. R., Viegas, C. A., Spee, B., Carvalho, P. P., & da Silva, C. L. (2025) · BMC Veterinary Research · doi:10.1186/s12917-025-05175-z
“MSC are non-tumorigenic and low-immunogenic, making them suitable for therapeutic applications [1, 15].”
Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3
Wu, Z., Zhong, J., Xu, C., Zhao, C., Yang, Q., Zhao, L., Lin, C., Zhang, S., & Zhong, J. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00323.2025 · Cited by 2
Ma, X., Zhang, Z., Liu, G., Shang, X., Yuan, S., Wei, C., Sun, X., Wang, Z., Wang, X., & Liu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1793151
“MSCs are involved in immunomodulatory activity, with pro-and anti-tumorigenic functions due to the interactions between MSCs and the inflammatory microenvironment (Harrell et al., 2021).”
Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment
Yang, Q., Zhang, W., Ji, K., Wang, Z., Gao, J., & Ding, J. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101151
“Finally, numerous therapeutic factors, such as small-molecule drugs (e.g., curcumin), nanomaterials (e.g., black phosphorus), and in vivo materials (e.g., mesenchymal stem cells), possess both antitumor and prorepair activities [ 188–190 ].”
Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects
Das, S., Goswami, H. R., Barman, I., & Talukdar, N. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121017 · Cited by 1
Immunomodulatory efficacy of culture condition-dependent modulation of mesenchymal stem cells
Sun, Q., Zhang, X., Dong, H., Mi, C., Geng, S., Li, Q., Zhang, J., Wang, X., & Wang, T. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05169-0
“…cord, placenta, and adipose tissue [12–14], and possess multi-directional differentiation potential, low immunogenicity, and immune regulatory advantages [15], making them an ideal starting material for tissue engineering [16], cell reprogramming [17–19], and cell trans-differentiation (Fig.”
Metadata
- Authors
- Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V.
- Affiliations
- Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, FL 34684, USA
- University of Kragujevac (RS)
- University of Bern (CH)
- Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-18
- Volume
- 22
- Issue
- 22
- Pages
- 12429
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8622564
- OpenAlex
- W3213583932
- Cited by
- 67
- References
- 47
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 23 · 2023: 17 · 2022: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Crohn’s and Colitis Organization (ECCO) (“The role of galectin 3 in acute colitis”)
- Swiss National Science Foundation (IZSEZ0 185546)
- Serbian Ministry of Science (ON1275069 and ON175071)
- Faculty of Medical Sciences University of Kragujevac (MP01/18)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- mesenchymal stem cells, antitumor immunity, tumor microenvironment, dendritic cells, macrophages, CD4+ T helper cells, CD8+ T cells, natural killer cells, myeloid-derived suppressor cells, regulatory T cells, tumor homing, exosomes, cancer immunotherapy
- MeSH terms
- Cell Communication, Cell Differentiation, Dendritic Cells, Gene Expression Regulation, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Macrophages, Neoplasms, T-Lymphocytes, Cytotoxic, Mesenchymal Stem Cell Transplantation, T-Lymphocytes, Regulatory, Exosomes, Tumor Microenvironment, Mesenchymal Stem Cells, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.